<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="10.17917/C77P49" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><h2>NCL Method GTA-11: Autophagic Dysfunction Assay‚ÄîQualitative Analysis of MAP LC3-I to LC3-II Conversion by Western Blot</h2><hr><p>Lysosomal dysfunction is recognized as a potential toxic mechanism for xenobiotics that can result in various pathological states.  There is concern that nanoparticles, in particular, may cause lysosomal pathologies, since they are likely to accumulate within lysosomes.  Lysosomal dysfunction could potentially result from nanoparticle biopersistance, or inhibition of lysosomal enzymes, such as inhibition of phospholipase resulting in phospholipidosis, or inhibition of lysosomal protein degradation resulting in lysosomal overload.  Possibly related to lysosomal dysfunction, nanoparticle exposure has also been shown to cause autophagic dysfunction, resulting in accumulation of autophagic vacuoles.  Common methods used to detect autophagic dysfunction include microscopy and protein modification assays, such as microtubule associated protein light chain 3-I (MAP LC3-I) lipidation.</p><h3>File name: protocols/20241210_19-26-30-161_NCL_Method_GTA-11.pdf</h3><h3>DOI: <a href = http://dx.doi.org/10.17917/C77P49>http://dx.doi.org/10.17917/C77P49</a></h3><h3>Resource Type:  Protocol</h3><h3>Data Access: <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a></h3></body></html>